专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130345075A1 Tissue Preservation and Fixation Method 有权
标题翻译：组织保存和固定方法
公开(公告)号：US20130345075A1
公开(公告)日：2013-12-26
申请号：US13836995
申请日：2013-03-15
申请人： Virginia A. Espina , Lance A. Liotta , David Geho
发明人： Virginia A. Espina , Lance A. Liotta , David Geho
IPC分类号： G01N1/30
CPC分类号： G01N1/30 , A01N1/00
摘要： This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that stabilizes the proteins in the sample and that has a sufficient water content for a stabilizer and/or a permeability enhancing agent to be soluble therein; (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; (3) a permeability enhancing agent; and (4) lactic acid. Methods and kits are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
摘要翻译：本发明涉及例如在室温下与包含磷蛋白的样品接触时可以固定和稳定细胞磷酸蛋白的组合物，保留细胞形态，并允许样品冷冻以产生适于分子的低温恒温器冷冻切片分析。组合物包含（1）稳定样品中蛋白质并且具有足够的水含量的固定剂，用于稳定剂和/或渗透性增强剂可溶于其中; （2）稳定剂，其包含（a）激酶抑制剂和（b）磷酸酶抑制剂和任选的（c）蛋白酶（例如蛋白酶）抑制剂; （3）渗透增强剂; 和（4）乳酸。描述了使用这种组合物来保存磷蛋白的方法和试剂盒。还描述了用于监测蛋白质降解的内源替代标记，包括翻译后修饰（例如磷酸化）的丧失，例如，从受试者中除去细胞或组织; 和外源性分子前哨蛋白（例如连接到磁性纳米颗粒的磷酸蛋白），其允许评价细胞或组织群体样品的加工历史。

2. 发明申请

US20100068690A1 TISSUE PRESERVATION AND FIXATION METHOD 有权
标题翻译：组织保存和固定方法
公开(公告)号：US20100068690A1
公开(公告)日：2010-03-18
申请号：US12447773
申请日：2007-10-26
申请人： Lance A. Liotta , Emmanuel F. Petricoin, III , David Geho , Virginia A. Espina
发明人： Lance A. Liotta , Emmanuel F. Petricoin, III , David Geho , Virginia A. Espina
IPC分类号： A01N1/02 , G01N33/48 , C07K14/00 , C12M1/00
CPC分类号： G01N1/30 , A01N1/00
摘要： This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
摘要翻译：本发明涉及例如在室温下与包含磷蛋白的样品接触时可以固定和稳定细胞磷酸蛋白的组合物，保留细胞形态，并允许样品冷冻以产生适于分子的低温恒温器冷冻切片分析。组合物包含（1）固定磷酸蛋白有效的固定剂，并且其具有足够的水含量可溶于稳定剂和/或渗透性增强剂）; （2）稳定剂，其包含（a）激酶抑制剂和（b）磷酸酶抑制剂和任选的（c）蛋白酶（例如蛋白酶）抑制剂; 和（3）渗透性增强剂（例如PEG）。描述了使用这种组合物来保存磷蛋白的方法。还描述了用于监测蛋白质降解的内源替代标记，包括翻译后修饰（例如磷酸化）的丧失，例如，以下从受试者中除去细胞或组织; 和外源性分子前哨蛋白（例如连接到磁性纳米颗粒的磷酸蛋白），其允许评价细胞或组织群体样品的加工历史。

3. 发明授权

US08460859B2 Tissue preservation and fixation method 有权
标题翻译：组织保存和固定方法
公开(公告)号：US08460859B2
公开(公告)日：2013-06-11
申请号：US12447773
申请日：2007-10-26
申请人： Virginia A. Espina , Lance A. Liotta , David Geho
发明人： Virginia A. Espina , Lance A. Liotta , David Geho
IPC分类号： A01N1/00
CPC分类号： G01N1/30 , A01N1/00
摘要： This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
摘要翻译：本发明涉及例如在室温下与包含磷蛋白的样品接触时可以固定和稳定细胞磷酸蛋白的组合物，保留细胞形态，并允许样品冷冻以产生适于分子的低温恒温器冷冻切片分析。组合物包含（1）固定磷酸蛋白有效的固定剂，并且其具有足够的水含量可溶于稳定剂和/或渗透性增强剂）; （2）稳定剂，其包含（a）激酶抑制剂和（b）磷酸酶抑制剂和任选的（c）蛋白酶（例如蛋白酶）抑制剂; 和（3）渗透性增强剂（例如PEG）。描述了使用这种组合物来保存磷蛋白的方法。还描述了用于监测蛋白质降解的内源替代标记，包括翻译后修饰（例如磷酸化）的丧失，例如，以下从受试者中除去细胞或组织; 和外源性分子前哨蛋白（例如连接到磁性纳米颗粒的磷酸蛋白），其允许评价细胞或组织群体样品的加工历史。

4. 发明申请

US20110250260A1 INHIBITION OF BRAIN ENZYMES INOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION 审中-公开
标题翻译：脑损伤后脑组织中脑组织的抑制作用
公开(公告)号：US20110250260A1
公开(公告)日：2011-10-13
申请号：US13035658
申请日：2011-02-25
申请人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
发明人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
IPC分类号： A61K31/713 , A61P25/28 , A61K9/127
CPC分类号： C12N15/1137 , A61K31/409 , C12N2310/14 , C12N2320/32 , C12Y114/99003
摘要： A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrinan in a manner that permits access to brain sites and/or the macula of the patient.
摘要翻译：治疗或抑制哺乳动物痴呆和/或黄斑变性进程的方法包括将含有siRNA的组合物给予血红素加氧酶-1（HO-1）或血红素加氧酶-2（HO-2），基质金属蛋白酶（MMP）抑制剂，胱天蛋白酶抑制剂或金属卟啉蛋白，其允许进入患者的脑部位和/或黄斑。

5. 发明申请

US20100047336A1 INHIBITION OF BRAIN ENZYMES INVOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION 审中-公开
标题翻译：参与谷氨酰胺转氨酶和谷氨酸降解的脑酶的抑制作用
公开(公告)号：US20100047336A1
公开(公告)日：2010-02-25
申请号：US12542635
申请日：2009-08-17
申请人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
发明人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
IPC分类号： A61K9/127 , A61K31/7052 , A61K31/555 , A61P25/28
CPC分类号： C12N15/1137 , A61K31/409 , C12N2310/14 , C12N2320/32 , C12Y114/99003
摘要： A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
摘要翻译：治疗或抑制哺乳动物痴呆和/或黄斑变性进程的方法包括将含有siRNA的组合物给予血红素加氧酶-1（HO-1）或血红素加氧酶-2（HO-2），基质金属蛋白酶（MMP）抑制剂，胱天蛋白酶抑制剂或金属卟啉以允许接近患者的脑部位和/或黄斑的方式。

6. 发明申请

US20090018094A1 INHIBITION OF BRAIN ENZYMES INVOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION 审中-公开
标题翻译：参与谷氨酰胺转氨酶和谷氨酸降解的脑酶的抑制作用
公开(公告)号：US20090018094A1
公开(公告)日：2009-01-15
申请号：US11948856
申请日：2007-11-30
申请人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
发明人： Wolff Kirsch , Lance A. Liotta , William Van Nostrand , Harry V. Vinters , Virginia A. Espina
IPC分类号： A61K31/7105 , A61P25/28
CPC分类号： C12N15/1137 , A61K31/409 , C12N2310/14 , C12N2320/32 , C12Y114/99003
摘要： A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
摘要翻译：治疗或抑制哺乳动物痴呆和/或黄斑变性进程的方法包括将含有siRNA的组合物给予血红素加氧酶-1（HO-1）或血红素加氧酶-2（HO-2），基质金属蛋白酶（MMP）抑制剂，胱天蛋白酶抑制剂或金属卟啉以允许接近患者的脑部位和/或黄斑的方式。

7. 发明申请

US20130137094A1 One-Step Cell and Tissue Preservative for Morphologic and Molecular Analysis 审中-公开
标题翻译：一步细胞和组织防腐剂用于形态和分子分析
公开(公告)号：US20130137094A1
公开(公告)日：2013-05-30
申请号：US13575001
申请日：2011-01-25
申请人： Virginia A. Espina , Lance A. Liotta , Claudius Mueller
发明人： Virginia A. Espina , Lance A. Liotta , Claudius Mueller
IPC分类号： G01N1/30
CPC分类号： G01N1/30 , A01N1/00
摘要： The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer. In still another embodiment, the compositions further include lactic acid at a concentration sufficient to maintain cellular nuclear volume at a level equivalent to aldehyde fixation of the same type of cell. In a further embodiment, the composition comprises: a) a precipitating fixative, b) a reversible/cleavable cross-linker, c) a permeation enhancer, d) a kinase inhibitor, e) a phosphatase inhibitor, and f) a carboxylic acid. In a still further embodiment, the invention comprises method for preserving a biological sample by contacting the sample with the composition of the invention under conditions effective for the preservation of the sample.
摘要翻译：本发明涉及保留动物组织，细胞和生物分子的一步化学组合物，例如人组织，人细胞和生物分子。它提高细胞，细胞器和核染色质的保真度和形态结构，并保持和增强免疫组织化学和流式细胞术的细胞抗原性，同时保留蛋白质，蛋白质的翻译后修饰和核酸。在一个实施方案中，组合物包含a）浓度低于25％（体积/体积）的非醛沉淀固定剂，b）靶向脂质相关分子的可逆/可切割蛋白质交联剂，以及c）可逆可逆/ 可裂解的蛋白质交联剂，其靶向水溶性分子。在另一个实施方案中，组合物还包含激酶抑制剂，磷酸酶抑制剂和渗透增强剂。在另一个实施方案中，组合物还包括浓度足以将细胞核体积保持在与相同类型细胞的醛固定相当的水平的乳酸。在另一个实施方案中，组合物包括：a）沉淀固定剂，b）可逆/可切割交联剂，c）渗透促进剂，d）激酶抑制剂，e）磷酸酶抑制剂，和f）羧酸。在又一个实施方案中，本发明包括通过在有效保存样品的条件下使样品与本发明的组合物接触来保存生物样品的方法。

8. 发明授权

US09086414B2 Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer 有权
标题翻译：磷酸化的C-ErbB2作为癌症诊断和治疗的优越预测因素
公开(公告)号：US09086414B2
公开(公告)日：2015-07-21
申请号：US13003206
申请日：2009-07-08
申请人： Emanuel F. Petricoin, III , Lance A. Liotta , Virginia Espina , Julia D. Wulfkuhle
发明人： Emanuel F. Petricoin, III , Lance A. Liotta , Virginia Espina , Julia D. Wulfkuhle
IPC分类号： A61K39/395 , A01N43/48 , G01N33/53 , G01N33/543 , G01N33/574 , C12Q1/68 , A61K31/517 , G01N1/30 , A61K39/00
CPC分类号： G01N33/57492 , A61K31/517 , A61K39/39558 , A61K2039/505 , C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N1/30 , G01N33/54366 , G01N33/574 , G01N33/57415 , G01N2033/57403 , G01N2333/71 , G01N2800/52
摘要： The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
摘要翻译：本发明提供了可靠的方法来鉴定具有上皮起源癌症的受试者的亚群，其特征在于高水平的磷酸化c-erbB2，其与通过IHC或FISH测量的总c-erbB2的过表达不相关，用于选择并包括c-erbB2直接治疗和治疗。此外，本发明提供了一种可靠的方法，用于确定由IHC和FISH确定为c-erbB2阳性的具有上皮起源癌症的受试者是否应从c-erbB2直接治疗中排除，磷酸化c-erbB2在上皮肿瘤组织中的显着水平。

9. 发明授权

US09012240B2 Hydrogel nanoparticle based immunoassay 有权
标题翻译：基于水凝胶纳米颗粒的免疫测定
公开(公告)号：US09012240B2
公开(公告)日：2015-04-21
申请号：US13061507
申请日：2009-08-26
申请人： Lance A. Liotta , Alessandra Luchini , Emanuel F. Petricoin , Virginia Espina
发明人： Lance A. Liotta , Alessandra Luchini , Emanuel F. Petricoin , Virginia Espina
IPC分类号： G01N33/549 , G01N33/53 , G01N33/544 , G01N33/558 , G01N33/52 , G01N33/543
CPC分类号： G01N33/521 , G01N33/54333 , G01N33/54346
摘要： An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.
摘要翻译：提供了在分析装置的流体流动路径内将多孔聚合物捕获纳米颗粒结合到样品采集容器中或预浸渍到多孔基质内的免疫测定装置。这种在免疫测定装置内的捕获颗粒的并入提高了灵敏度，同时在加载免疫测定装置之前消除了样品预处理的要求。优选的实施方案是含有捕获纳米颗粒的芯壳诱饵，其在一个步骤中在溶液中进行三个功能：a）分子筛分，b）目标分析物螯合和浓缩，以及c）防止降解。捕获颗粒的聚合物基质可以由具有结构单体和亲和单体的共聚物制成，亲和单体具有将分析物吸引到捕获颗粒的性质。该设备可用于生物医学应用的护理点诊断分析以及环境，病原体和化学或生物威胁鉴定的现场部署测定。

10. 发明申请

US20110207627A1 EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA 审中-公开
标题翻译：用于多发性骨髓瘤的生物骨髓细胞的筛查治疗
公开(公告)号：US20110207627A1
公开(公告)日：2011-08-25
申请号：US13057978
申请日：2009-08-12
申请人： Lance A. Liotta , Emanuel F. Petricoin, III , Virginia Espina
发明人： Lance A. Liotta , Emanuel F. Petricoin, III , Virginia Espina
IPC分类号： C12Q1/02 , G01N33/566 , C40B30/04 , C12Q1/37 , C12Q1/48 , H01J49/26
CPC分类号： G01N33/56972 , G01N33/5011 , G01N2333/70596 , G01N2510/00 , G01N2800/52
摘要： Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.
摘要翻译：提供了选择多发性骨髓瘤患者的治疗方法。在开始治疗方案之前，从患者中分离骨髓抽吸物并与一种或多种候选治疗剂一起温育。该方法确定最有可能为特定个体产生最佳结果的治疗或疗法组合。除了改善临床结果之外，这种诊断性评估通过避免无效疗法，大大降低了医疗保健成本。还提供了用于鉴定多发性骨髓瘤治疗的筛选试验。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式